JP2023008912A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023008912A5 JP2023008912A5 JP2022104196A JP2022104196A JP2023008912A5 JP 2023008912 A5 JP2023008912 A5 JP 2023008912A5 JP 2022104196 A JP2022104196 A JP 2022104196A JP 2022104196 A JP2022104196 A JP 2022104196A JP 2023008912 A5 JP2023008912 A5 JP 2023008912A5
- Authority
- JP
- Japan
- Prior art keywords
- drugs
- alkyl
- pharmaceutical composition
- disorders
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 39
- 229940079593 drug Drugs 0.000 claims 29
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- 125000000217 alkyl group Chemical group 0.000 claims 24
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 16
- 229910052736 halogen Inorganic materials 0.000 claims 14
- 150000002367 halogens Chemical class 0.000 claims 14
- 229940124597 therapeutic agent Drugs 0.000 claims 10
- 208000020016 psychiatric disease Diseases 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 208000015114 central nervous system disease Diseases 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- 206010012289 Dementia Diseases 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 4
- 239000001961 anticonvulsive agent Substances 0.000 claims 4
- 150000001721 carbon Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 208000020925 Bipolar disease Diseases 0.000 claims 3
- 208000013200 Stress disease Diseases 0.000 claims 3
- 208000029560 autism spectrum disease Diseases 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- 208000019116 sleep disease Diseases 0.000 claims 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000017164 Chronobiology disease Diseases 0.000 claims 2
- 208000012239 Developmental disease Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000016285 Movement disease Diseases 0.000 claims 2
- 208000027626 Neurocognitive disease Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 201000001880 Sexual dysfunction Diseases 0.000 claims 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 2
- 239000002269 analeptic agent Substances 0.000 claims 2
- 229940035676 analgesics Drugs 0.000 claims 2
- 229940035674 anesthetics Drugs 0.000 claims 2
- 239000000730 antalgic agent Substances 0.000 claims 2
- 229940125713 antianxiety drug Drugs 0.000 claims 2
- 229940125681 anticonvulsant agent Drugs 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- 239000000164 antipsychotic agent Substances 0.000 claims 2
- 239000002249 anxiolytic agent Substances 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 230000003542 behavioural effect Effects 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 206010013663 drug dependence Diseases 0.000 claims 2
- 239000003193 general anesthetic agent Substances 0.000 claims 2
- 206010022437 insomnia Diseases 0.000 claims 2
- 230000004060 metabolic process Effects 0.000 claims 2
- 201000003631 narcolepsy Diseases 0.000 claims 2
- 231100000872 sexual dysfunction Toxicity 0.000 claims 2
- 201000002859 sleep apnea Diseases 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 206010060860 Neurological symptom Diseases 0.000 claims 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 125000005907 alkyl ester group Chemical group 0.000 claims 1
- 229940124433 antimigraine drug Drugs 0.000 claims 1
- 230000005978 brain dysfunction Effects 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 229940001470 psychoactive drug Drugs 0.000 claims 1
- 239000004089 psychotropic agent Substances 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021108402 | 2021-06-30 | ||
| JP2021108402 | 2021-06-30 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023008912A JP2023008912A (ja) | 2023-01-19 |
| JP2023008912A5 true JP2023008912A5 (https=) | 2023-12-12 |
| JP7655885B2 JP7655885B2 (ja) | 2025-04-02 |
Family
ID=85112098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022104196A Active JP7655885B2 (ja) | 2021-06-30 | 2022-06-29 | 脂肪族酸アミド誘導体を含有する医薬組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7655885B2 (https=) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880930A (en) * | 1987-11-30 | 1989-11-14 | New James S | Psychotropic acyclic amide derivatives |
| EP0732332B1 (en) * | 1995-03-17 | 2001-12-19 | Aventis Pharmaceuticals Inc. | Substituted benzothienylpiperazines, their use as medicaments, and processes for their preparation |
| JP2006508101A (ja) * | 2002-11-08 | 2006-03-09 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | フェニルアルキルおよびピリジルアルキルピペラジン誘導体 |
| AU2006239302B2 (en) * | 2005-04-26 | 2011-07-07 | Hypnion, Inc. | Benzisoxazole piperazine compounds and methods of use thereof |
| AU2011225095C1 (en) * | 2010-03-11 | 2017-01-19 | Sumitomo Dainippon Pharma Co., Ltd. | N-Acyl cyclic amine derivative or pharmaceutically acceptable salt thereof |
| KR20220120625A (ko) * | 2019-12-24 | 2022-08-30 | 스미토모 파마 가부시키가이샤 | 지방족 산 아미드 유도체 |
-
2022
- 2022-06-29 JP JP2022104196A patent/JP7655885B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018058890A5 (https=) | ||
| JP2021105032A5 (https=) | ||
| JP2021519267A5 (https=) | ||
| JP2018104454A5 (https=) | ||
| RU2015143466A (ru) | Нейроактивные стероиды и способы их применения | |
| JP2013512926A5 (https=) | ||
| JP2017531020A5 (https=) | ||
| RU2008127501A (ru) | Сульфонилзамещенные 1н-индолы в качастве лигандов 5-гидрокситриптаминовых рецепторов | |
| RU2018130727A (ru) | Органические соединения | |
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| WO2005079802A8 (en) | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | |
| JP2008534627A5 (https=) | ||
| JP2018505898A5 (https=) | ||
| AR069260A1 (es) | Compuesto 1-[2-(2, 4-dimetilfenilsulfanil)fenil]piperazina.usos terapeuticos de compuestos que tienen actividad combinada de sert (transportador de serotonina), 5-ht3 (receptor 3 de 5-hidroxitriptamina) y 5-ht1a (receptor 1a de 5-hidroxitriptamina).metodo de tratamiento. | |
| JP2022515766A5 (https=) | ||
| JP2003507367A5 (https=) | ||
| RU2009136330A (ru) | Тетрагидроизохинолиновые соединения в качестве модуляторов гистаминового н3 рецептора | |
| JP2014526435A5 (https=) | ||
| JP2015506382A5 (https=) | ||
| JP2016155815A5 (https=) | ||
| JP2024507638A5 (https=) | ||
| JP2015521642A5 (https=) | ||
| JP2024521747A5 (https=) | ||
| JP2019516756A5 (https=) | ||
| US20140371208A1 (en) | Methods of treating disease-induced ataxia and non-ataxic imbalance |